Yifeng Pharmacy Chain Co., Ltd.: history, ownership, mission, how it works & makes money

From a single store founded in Changsha in June 2001 by chairman Gao Yi to a national powerhouse listed on the Shanghai Stock Exchange as 603939, Yifeng Pharmacy Chain has scaled aggressively-operating over 14,600 stores and serving more than 87 million members-while blending retail, wholesale, e-commerce and digital healthcare services; institutional investors hold about 20.02% of shares as the company pursues expansion supported by technology (SAP/ERP, WMS, AI and blockchain), internet hospitals and chronic disease programs, and its recent financials underscore the momentum with revenue of CN¥5.56 billion and net profit of CN¥344.51 million for the quarter ended September 30, 2025, positioning Yifeng to capture demand from China's aging, health-conscious population.

Yifeng Pharmacy Chain Co., Ltd. (603939.SS): Intro

• Founded: June 2001 (Changsha, Hunan) - Founder & CEO: Gao Yi
• First expansion outside Hunan: October 2004 (Shanghai Yifeng Pharmacy Chain Co., Ltd.)
• Further regional expansion: May 2006 (Jiangsu Yifeng), October 2008 (Jiangxi Yifeng)
• Listed on Shanghai Stock Exchange: February 17, 2015 - Ticker: 603939 (first pharmacy chain on the main board)

• Retail pharmacy sales (prescription drugs and OTC medicines): core revenue engine through both self-operated and franchised stores
• Fast-moving consumer health & wellness products: margin-enhancing cross-sell (supplements, personal care, medical devices)
• Value-added services: community pharmacy services, chronic disease management, medication consultation, and basic medical devices/services
• Wholesale and supply chain optimization: procurement scale and distribution network reduce COGS and enable private-label and branded assortments

• Omnichannel retail: in-store sales (flagship and community pharmacies) combined with online ordering, app-based membership, and integrated delivery to capture frequent, convenience-led purchases.
• Franchise + direct operation model: rapid network growth via franchising while maintaining company-run stores in strategic urban markets to retain brand control and test formats.
• Membership-driven demand: loyalty programs and digital platforms drive repeat purchases, personalized promotions, and higher basket sizes among 87M+ members.
• Supply chain scale & procurement: centralized purchasing lowers cost of goods sold; private-label introductions improve gross margin.
• Service monetization: paid medication management, chronic disease follow-ups, vaccination & basic clinical services in select stores add higher-margin revenue streams.

• Listed: 2015 on Shanghai Stock Exchange (603939.SS), providing access to public capital for store expansion and supply-chain investments.
• Investor relations resources: Exploring Yifeng Pharmacy Chain Co., Ltd. Investor Profile: Who's Buying and Why?

Yifeng Pharmacy Chain Co., Ltd. (603939.SS): History

• Founder & Chairman: Gao Yi - holds a significant stake and retains strategic control.
• Institutional ownership: ~20.02% - reflecting notable participation by financial entities.
• Public float: Remaining shares held by retail and other public investors.
• Listing: Shanghai Stock Exchange - active trading provides liquidity for shareholders.

• How ownership supports strategy: The founder's controlling stake enables consistent long-term direction; institutional holders provide capital discipline and endorsement; public float supplies liquidity for M&A and expansion financing.
• Investor access: Active SSE listing facilitates secondary-market transactions and broad investor participation.

Yifeng Pharmacy Chain Co., Ltd. (603939.SS): Ownership Structure

• Mission: Provide accessible, high‑quality pharmaceutical products and integrated health services to communities across China.
• Customer focus: Prioritizes satisfaction through wide product assortment, pharmacy counseling and after‑sales care.
• Innovation: Invests in digital platforms, e‑commerce, supply‑chain IT and in‑store tech to improve engagement and efficiency.
• Integrity & transparency: Publishes audited financials and compliance disclosures to build trust with customers, regulators and partners.
• Social responsibility: Participates in public health campaigns, community clinics and programs to improve medication accessibility.
• Sustainability: Balances growth with environmental and social considerations in store expansion and operations.

• Retail pharmacy sales: Prescription and OTC medicines sold through brick‑and‑mortar stores and omnichannel platforms.
• Health services: In‑store consultation, chronic disease management, vaccination and screening services.
• Private label & product margin: Higher‑margin own‑brand health supplements and consumer healthcare products.
• Distribution & procurement: Centralized purchasing and logistics reduce costs and improve gross margins.
• Digital channels: E‑commerce, mini‑programs and O2O fulfillment increase customer lifetime value and lower acquisition costs.

• Major shareholders: mix of institutional investors, founding/management holdings and public float on the Shanghai Stock Exchange (603939.SS).
• Board & oversight: Board composed of independent and executive directors with audit and risk committees to ensure regulatory compliance.
• Corporate actions: Uses M&A, regional partnerships and franchising models to accelerate store network growth.

Yifeng Pharmacy Chain Co., Ltd. (603939.SS): Mission and Values

• Dual business model: retail (brick-and-mortar & franchised pharmacies) and wholesale distribution to hospitals, clinics, and third-party pharmacies.
• Omnichannel sales: physical stores complemented by an e-commerce platform and app for O2O fulfillment, prescription refills and health product sales.
• Healthcare services: chronic disease management programs, pharmacy counseling, and operation of internet hospital services connecting physicians, pharmacists and patients.
• Advanced supply chain & IT: SAP/ERP backbone, WMS for warehouse operations, and adoption of AI for demand forecasting plus blockchain pilots for drug traceability.

• Store network: over 14,600 stores across China (combination of directly-operated and franchised outlets), providing broad geographical coverage including county and township markets.
• Workforce and partners: tens of thousands of employees and licensed pharmacists; partnerships with domestic suppliers, manufacturers and logistics providers.

• Inventory and logistics: centralized distribution centers feeding regional warehouses; WMS-driven picking and replenishment with target inventory turnover in the mid-single digits annually.
• AI & analytics: demand forecasting, dynamic pricing pilots, and churn/loyalty modeling to improve same-store sales and customer retention.
• Blockchain pilots: traceability projects for high-risk drug categories to comply with national drug traceability initiatives.
• Digital patient engagement: online appointment booking, teleconsultation through internet hospitals, and chronic disease follow-up via mobile platforms.

• Retail margins: markup on OTC and consumer health products; narrow on reimbursable prescription drugs but volume-driven.
• Wholesale margins: negotiated procurement margins, logistics fees and scale advantages from centralized purchasing.
• Service monetization: internet hospital consultation fees, subscription-based chronic disease management and paid pharmacy services.
• Economies of scale: centralized procurement, private-label expansion and tiered supplier contracts reduce COGS and support margin expansion.

• Store footprint expansion in lower-tier cities and rural counties to capture under-penetrated markets.
• Franchise model to accelerate openings with lower capital intensity while maintaining brand standards and procurement control.
• Digitization: SAP/ERP & WMS investments to shorten replenishment cycles and reduce stockouts; AI to optimize assortments per store.
• Integration of internet hospitals and chronic disease services to increase customer lifetime value and prescription retention.

Yifeng Pharmacy Chain Co., Ltd. (603939.SS): How It Works

• Core retail sales: pharmacy outlets sell prescription drugs, OTC medicines, health supplements, cosmetics, and personal care products.
• Wholesale distribution: supplies medicines and consumer health products to smaller pharmacies, clinics, and institutional buyers.
• E‑commerce: omnichannel platform and third‑party marketplaces extend reach beyond brick‑and‑mortar customers.
• Health services: chronic disease management programs, pharmacy clinical services, and internet hospital operations provide service revenue and deepen customer relationships.
• Customer loyalty and membership: data-driven promotions, loyalty points and membership tiers increase repeat purchase rates and average basket size.

• High-density store network (14,600+ locations) creates broad geographic coverage and frequent footfall to support sales volume and market penetration.
• Centralized procurement and regional distribution centers lower COGS and improve inventory turnover.
• Integrated omni-channel CRM ties online orders, in-store pickup and delivery, and loyalty incentives into a single customer view to boost retention.
• Value-added services (chronic disease programs, internet hospital consultations) increase customer lifetime value and diversify margins away from low-margin retail SKUs.

• Store count: 14,600+ retail outlets nationwide.
• Same‑store sales: typically positive in mature urban clusters driven by loyalty and services (varies by year/region).
• Gross margin profile: retail pharmacy margins are moderate; health services and specialty product lines command higher margins.
• CapEx and expansion: ongoing investment in new stores and digital capabilities; regional distribution centers to support logistics.
• Profit drivers: sales volume through dense store footprint, higher-margin service offerings, digital sales growth, and procurement efficiencies.

• Store expansion into lower‑penetration cities and township markets to capture incremental foot traffic.
• Upselling and cross‑selling: combining chronic disease services with medication adherence programs increases recurring purchasing.
• Improved online conversion and logistics (O2O fulfillment, same‑day delivery) to raise e‑commerce contribution.
• Private label and higher‑margin wellness products to improve gross margins.
• Data monetization via targeted promotions and partnerships with healthcare providers and insurers.

Yifeng Pharmacy Chain Co., Ltd. (603939.SS): How It Makes Money

• Retail pharmacy sales from >14,600 stores (direct and franchised), covering OTC drugs, prescription fulfillment, health supplements, medical devices and FMCG.
• E-commerce and omni-channel sales - online orders, mini-programs and third‑party platforms (online accounted for ~30% of total revenue in FY2022; digital share rising thereafter).
• Membership and loyalty programs - >87 million members driving repeat purchases and targeted promotions.
• Healthcare services - in-store clinics, chronic disease management, medication counseling and diagnostic/testing partnerships.
• Supply chain and distribution margins - procurement scale, private‑label goods and logistic optimization (SAP/ERP, WMS implementations).

• Technology & operations: SAP/ERP and WMS rollouts reduce stockouts, shorten replenishment cycles and lower working capital intensity.
• Growth levers: store network expansion, conversion of franchisees to standardized formats, cross‑sell via membership data and expansion into eldercare/diagnostics as China's population ages.
• Profitability focus: mix shift toward higher‑margin private label and healthcare services, plus improved online fulfillment efficiency.